Vivus (VVUS ) shares have moved up strongly on the news that FDA has agreed to an early re-submission of the QNEXA NDA for the treatment of obesity.
The road is not all clear for Vivus. There are still major issues that need to be resolved by Vivus including birth defect concerns, cardiovascular concerns, and epilepsy concerns.
If and when six screens of the ZYX Change Method are satisfied, we will issue a buy signal on the Real Time Feed of the ZYX Buy Change Alert.
